Discover Oncology (Dec 2024)

CMTM6 status predicts survival in head and neck squamous cell carcinoma and correlates with PD-L1 expression

  • Anne-Sophie Becker,
  • Nicolas Wieder,
  • Sarah Zonnur,
  • Annette Zimpfer,
  • Mareike Krause,
  • Björn Schneider,
  • Daniel Fabian Strüder,
  • Ann-Sophie Burmeister,
  • Andreas Erbersdobler,
  • Christian Junghanss,
  • Claudia Maletzki

DOI
https://doi.org/10.1007/s12672-024-01554-4
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract We retrospectively analyzed 129 treatment-naïve head and neck squamous cell carcinomas (HNSCCs) for the expression of programmed death ligand 1 (PD-L1), CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6), tumor-infiltrating leukocytes (TILs), and tumor-associated macrophages (TAMs). We evaluated the relationships among these markers, human papilloma virus (HPV) status, and overall survival (OS). PD-L1 and CMTM6 (combined positive score (CPS) ≥ 1 and ≥ 5) were detected in ~ 70% of HNSCCs. HPV status had insignificant effects on marker expression. Most PD-L1-positive cases showed concomitant CMTM6 expression with comparable staining patterns. While PD-L1 and CMTM6 mRNA expression levels correlated with PD-L1 and CMTM6 protein status, no significant correlation was observed for PD-L1 and CMTM6 mRNA expression. Tumors expressing PD-L1 (p 1 were prognostically relevant. In addition to HPV status, PD-L1 and CD8+ T cells, CMTM6 was identified as an independent prognostic factor using a multivariate Cox regression analysis. PD-L1 and CMTM6 correlated with TILs and CD8+ cells but not with HPV. Our results identified CMTM6 as an important interaction partner in the crosstalk between TILs, CD8+ T cells, and PD-L1, which mediates anticancer efficacy. Assessments of CMTM6 may be helpful for prognostic prediction, and it may serve as a reliable biomarker for immunotherapy selection.

Keywords